

**Metabolic adaptability in metastatic breast cancer by
AKR1B10-dependent balancing of glycolysis and fatty acid oxidation**

^{1,3}Antoinette van Weverwijk, ²Nikolaos Koundouros, ¹Marjan Iravani,
¹Matthew Ashenden, ¹Qiong Gao, ²George Poulogiannis, ^{1,4}Ute Jungwirth and
^{1,*}Clare M. Isacke

¹The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK

²Department of Cancer Biology, The Institute of Cancer Research, London, UK.
Division of Computational and Systems Medicine, Department of Surgery and Cancer, Imperial College London, London, UK

Current address: ³Division of Tumor Biology & Immunology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.

⁴Department of Pharmacy & Pharmacology, Centre for Therapeutic Innovation, University of Bath, Bath BA2 7AY, UK

Running title: Regulation of fatty acid oxidation during breast cancer metastasis

Keywords: breast cancer metastasis, metabolic regulation, AKR1B10, fatty acid oxidation, lung metastasis

***Corresponding Author:** Clare M. Isacke, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, 237 Fulham Road, London, UK.
Tel: +44 20 7153 5510; Fax: +44 20 7153 5340; Email: clare.isacke@icr.ac.uk

Conflicts of Interest: The authors declare no potential conflicts of interest

Figures: 6 figures plus 4 Supplementary Tables and 5 Supplementary Figures

Abstract

The different stages of the metastatic cascade present distinct metabolic challenges to tumour cells and an altered tumour metabolism associated with successful metastatic colonisation provides a therapeutic vulnerability in disseminated disease. We identify the aldo-keto reductase AKR1B10 as a metastasis enhancer that has little impact on primary tumour growth or dissemination but promotes effective tumour growth in secondary sites and, in human disease, is associated with an increased risk of distant metastatic relapse. AKR1B10^{High} tumour cells have reduced glycolytic capacity and dependency on glucose as fuel source but increased utilisation of fatty acid oxidation. Conversely, in both 3D tumour spheroid assays and *in vivo* metastasis assays, inhibition of fatty acid oxidation blocks AKR1B10^{High}-enhanced metastatic colonisation with no impact on AKR1B10^{Low} cells. Finally, mechanistic analysis supports a model in which AKR1B10 serves to limit the toxic side effects of oxidative stress thereby sustaining fatty acid oxidation in metabolically challenging metastatic environments.

Introduction

A defining characteristic of primary tumour cells is an ability to alter their metabolism, which provides the energy and metabolites required to sustain survival in nutrient and oxygen limiting conditions. In disseminating tumour cells this need for an altered metabolism becomes more acute, as cells have to avoid anoikis-mediated cell death in the circulation and face the challenge of surviving at the metastatic site before establishment of a productive metastatic colony. Moreover, different metastatic sites pose distinct metabolic challenges to the tumour cell^{1,2}. In breast cancers, these altered metabolic dependencies are now being defined but the molecular mechanisms regulating this metabolic adaptability have yet to be identified.

Here we report the analysis of a syngeneic *in vivo* RNAi screen to identify putative metastasis enhancers. Among the top hits from the screen was the aldo-keto reductase, *Akr1b8*. *Akr1b8*, and its human orthologue AKR1B10³ are NADPH-dependent enzymes that can reduce a variety of carbonyl substrates⁴. These include the conversion of retinal to retinol^{5,6} resulting in decreased retinoic acid signalling, conversion of the isoprenyl aldehydes farnesal and geranylgeranal to farnesol and geranylgeranol⁷ generating precursors for protein prenylation and the reduction of cytotoxic aldehydes⁸. Although *AKR1B10* expression is upregulated in a variety of cancers including hepatocellular^{9,10}, lung¹¹, pancreatic¹² and breast^{13,14}, the mechanism by which elevated levels of AKR1B10 enhances metastasis is not known. We demonstrate that AKR1B10^{High} cells are characterised by a reduced glycolytic capacity and an increased utilisation of fatty acid oxidation (FAO), and that this altered metabolism is required for successful colonisation of secondary sites but not primary tumour growth or metastatic dissemination.

Results

Akr1b8/AKR1B10 promotes breast cancer metastasis

To identify novel enhancers of breast cancer metastasis we analysed a syngeneic *in vivo* shRNA screen, focusing on shRNAs that were significantly under-represented in the 4T1-Luc tumour-bearing lungs of BALB/c mice compared to preinoculation 4T1-Luc mouse mammary carcinoma cells (Fig. 1a; see Methods). 81 shRNAs were found to be significantly depleted (Z-score <-2) in the metastatic lung samples (Fig. 1b) and were then filtered by removing shRNAs that (a) did not align to the predicted target gene, (b) were significantly depleted in less than 3 of the 4 biological replicates, (c) targeted genes with expression in the lowest 50th percentile based on gene expression profiling of 4T1 cells directly isolated from tumours¹⁵, and (d) when comparing the preinoculation cells to the initial plasmid library (Fig. 1a) showed a significant difference in abundance (Z-score >2 or <-2) indicating an effect on cell

viability. Filtering resulted in a shortlist of 23 significantly depleted shRNAs targeting genes encoding putative metastasis enhancers (Fig. 1c and Supplementary Table 1). Within this shortlist are known regulators of breast cancer progression and metastasis such as matrix metalloproteinase 9 (*Mmp9*)¹⁶, cathepsin D (*Ctsd*)¹⁷, insulin-like growth factor 1 (*Igf1*)¹⁸ and MET (*Met*)¹⁹, as well as inhibitors of apoptosis such as BCL2-like 2 (*Bcl2l*), BCL2 associated athanogene 1 (*Bag1*), nucleolar protein 3 (*Nol3*) and protein kinase C eta (*Prkch*), providing confidence in the ability of the screen to uncover novel metastatic regulators.

Of particular interest was the presence of the metabolic enzyme aldo-keto reductase 1b8 (*Akr1b8*) in this shortlist. The human orthologue of *Akr1b8*, *AKR1B10*, has been reported to be upregulated in a number of cancer types including breast cancer^{13,14}, but the clinical and metabolic consequences of this altered expression have not been investigated. First, 4T1-Luc cells were transduced with lentiviral constructs containing empty vector (shCTRL), a non-targeting shRNA (shNTC) or two independent shRNAs targeting *Akr1b8* (shAkr1b8-4 and shAkr1b8-7) (Supplementary Figure 1a). Consistent with the screening data, where we compared shRNA representation in the starting plasmid pools with the preinoculation cells, *Akr1b8* knockdown had no significant effect on cell viability when cultured in full medium *in vitro* (Supplementary Figure 1b). By contrast, following intravenous inoculation, the two *Akr1b8* knockdown cell lines showed a significant decrease in lung colonisation as monitored by *in vivo* IVIS imaging, *ex vivo* lung weight, and quantification of tumour burden (Fig. 1d).

Although these data validate the *in vivo* shRNA screen, intravenous inoculation does not assess the full metastatic ability of tumour cells. Consequently, we next performed a spontaneous metastasis assay in which cells were inoculated orthotopically into 4th mammary fat pad of BALB/c mice (Fig. 1e, Supplementary Figure 2). No differences were observed in tumour take or primary tumour weight at the end of the experiment, however, there was a notable reduction in lung metastasis

in both the *Akr1b8-4* and *Akr1b8-7* knockdown groups compared to the control shNTC and shCTRL groups. In this experiment, there was no significant difference in the number of 4T1-Luc tumour cell colonies derived from arterial blood collected at necropsy (Fig. 1f) indicating that the metastatic impairment in the 4T1-Luc knockdown cells was not due to reduced survival in the circulation. Consistent with this observation, there was no significant difference in cell apoptosis between shNTC and shAkr1b8-4 cells when plated into non-adherent culture *in vitro* (Fig. 1g). Finally, to address whether the metastatic impairment resulted from impairment of tumour cell survival after lodging in the lung vasculature, 4T1-Luc shNTC and shAkr1b8 cells were labelled with cell tracker dyes, mixed at a 1:1 ratio and injected via the tail vein into BALB/c mice (Fig. 1h). Imaging of the lungs 1 hour post-injection confirmed that equal number of cells had been inoculated. Examination of lungs 16 hours post-injection revealed no significant difference between the number of control and *Akr1b8*-knockdown tumour cells retained in the lungs. Together these data indicate that *Akr1b8* expression does not impact on survival in the circulation or lodging in the vasculature but is required for efficient colonisation of tumour cells within the metastatic site.

Expression of *AKR1B10* correlates with metastatic relapse

To address the clinical relevance of the data obtained with the 4T1 mouse models, expression of *AKR1B10*, the human orthologue of murine *Akr1b8*³, was analysed in human primary breast cancers present in the TCGA database. Within the intrinsic subtypes, *AKR1B10* expression is significantly higher in the HER2-enriched and basal-like breast cancers compared to luminal A and luminal B cancers (Fig. 2a) and analysis by receptor expression revealed significantly higher *AKR1B10* expression in ER- compared to ER+ breast cancers, and in HER2+ compared to HER2- breast cancers (Fig. 2a). The latter finding is consistent with a previous report that overexpression of *AKR1B10* correlates with HER2 positivity in ductal carcinoma *in*

situ (DCIS)²⁰. An equivalent pattern of *AKR1B10* expression is seen in the Neve *et al.* dataset derived from profiling a large panel of breast cancer cell lines²¹ (Supplementary Figure 3a). Consistent with these published data, western blot (Fig. 2b, upper panel) and RTqPCR (Supplementary Figure 3b) analysis of a smaller panel of breast cancer cell lines revealed low levels of AKR1B10 protein and mRNA in the ER+ ZR75.1 and MCF7 lines and high levels in the basal-like BT20, MDA-MB-468 and HCC1395 lines (Fig. 2b, upper panel). For further studies, AKR1B10 was ectopically expressed in the AKR1B10^{Low} MDA-MB-231 and MDA-MB-453 lines and expression was knocked down by shRNA in the AKR1B10^{High} HCC1395 line (Fig. 2b, lower panel). Levels of ectopically expressed protein were equivalent to that found in AKR1B10^{High} lines, while shRNA knockdown reduced protein levels to that observed in AKR1B10^{Low} lines.

As with the 4T1-Luc cells (Supplementary Figure 1b), the human breast cancer cell lines with altered AKR1B10 levels showed no difference in *in vitro* viability as monitored in a colony formation assay (Fig. 2c), yet when inoculated intravenously into BALB/c Nude mice, AKR1B10^{High} MDA-MB-231 cells gave rise to a significantly increased tumour burden in the lungs compared to AKR1B10^{Low} MDA-MB-231 cells (see vehicle-treated cohorts in Fig. 6b). Again, there was no significant difference in cell survival when cells were plated in non-adherent culture (Fig. 2d) nor in the ability of the cells to survive after lodging in the lung vasculature (Fig. 2e), supporting the hypothesis that AKR1B10 functions to maintain efficient growth of tumour cells within the metastatic tissue.

Consistent with these findings, in a dataset of 1,746 unselected breast cancers²², high expression of *AKR1B10* significantly correlated with reduced distant metastasis-free survival when considering all patients or only ER- patients. A similar trend was seen in HER2+ patients, however, the number of samples was too low to reach statistical significance (Fig. 2f). No association with outcome was seen in ER+ only patients. As AKR1B10 has been associated with chemoresistance via its ability

to metabolise anti-cancer drugs²³, we also examined the subset of untreated patients (Supplementary Figure 3c). Again, high expression of *AKR1B10* (upper quartile) was significantly associated with reduced distant metastasis-free survival in ER-, but not ER+, breast cancer patients.

AKR1B10^{High} cancer cells have increased dependency on FAO

Via their oxidoreductase activity, members of the AKR family including *AKR1B10* have been implicated as regulators of cellular metabolism. Aerobic glycolysis, also known as the Warburg effect, is a common feature of many cancers and characterised by increased metabolism of glucose to lactate, which is transported out of the cell resulting in local acidification. The Seahorse XF Glycolysis Stress test was used to assess glycolytic function of cells by measuring the extracellular acidification rate (ECAR) in the media (Fig. 3a). Following addition of glucose, the glycolytic rate was significantly reduced in *AKR1B10*^{High}, compared to *AKR1B10*^{Low}, breast cancer cells, as was their glycolytic capacity and glycolytic reserve. Moreover, glucose uptake was significantly reduced in all three *AKR1B10*^{High} cell lines (Fig. 3b), indicating that *AKR1B10*^{High} cells have a reduced requirement for glucose. Consistent with this hypothesis, in 2D culture *AKR1B10*^{High} and *AKR1B10*^{Low} cells showed only a modest difference in cell growth when cultured in full DMEM (4.5 g L⁻¹ D-glucose) but in low glucose (LG) DMEM (1 g L⁻¹ D-glucose) *AKR1B10*^{Low} cells showed a significantly impaired growth rate (Fig. 3c). These data were recapitulated first in a 3D *in vitro* assay where *AKR1B10*^{High} tumour spheroids showed increased growth in LG DMEM compared to the *AKR1B10*^{Low} spheroids (Fig. 3d) and in colony forming assays where *AKR1B10*^{High} cells were significantly more tolerant to low glucose conditions (Fig. 3e)

In addition to aerobic glycolysis, tumour cells can utilise glutamine and/or fatty acids to generate sufficient ATP and metabolites to support cellular activities. As

AKR1B10^{High} cells have a reduced glycolytic function, take up less glucose and are better able to survive in low glucose conditions, we used the Seahorse XF Mito Fuel Flex Test to monitor the dependency on glutamine or fatty acids as an alternative source of energy. In none of the three cell lines was there evidence of an increased dependency on glutamine oxidation in the AKR1B10^{High} cells (Fig. 4a, left panel), whereas two out of three AKR1B10^{High} breast cancer cell lines showed an increased dependency on fatty acid oxidation (FAO) compared to their matched AKR1B10^{Low} counterparts (Fig. 4a, right panel). Moreover, AKR1B10^{High} cells showed a significantly increase change in OCR (Δ OCR) following addition of the FAO substrate palmitate-BSA (Fig. 4b).

To address clinical relevance of these findings, we used a FAO 88-gene signature (FAO88; see Methods) and demonstrated that *AKR1B10* expression positively correlated with a high FAO88 score in triple negative (TN) and ER- breast cancer, but not in ER+ breast cancers (Fig. 4c) both in the TCGA dataset and in the dataset of Hatzis *et al.* containing 508 breast cancer patients treated with neoadjuvant chemotherapy²⁴. In the Hatzis dataset there were insufficient numbers of HER2+ breast cancers for analysis, however, in the intrinsic subtype of HER2-enriched tumours high *AKR1B10* expression again positively correlated with a high FAO88 score (Fig. 4c).

The processes of FAO and fatty acid synthesis are usually mutually exclusive due to their regulation by negative feedback²⁵. It was notable that *AKR1B10* expression in human breast cancers positively correlated with the key FAO transcriptional regulator, peroxisome proliferator-activated receptor gamma coactivator 1 alpha (*PPARGC1A*, also known as PGC-1 α) ($P=0.009$) and negatively correlated with the activators for fatty acid synthesis, acetyl-CoA carboxylase β (*ACACB*; $P=0.047$) and acyl-CoA synthetase long chain family member 1 (*ACSL1*; $P<0.001$), Spearman's correlation. Consistent with these clinical datasets, fatty acid synthesis as monitored by incorporation of ¹⁴C-acetate in lipids was significantly

reduced in AKR1B10^{High} cells (Fig. 5a). Given this negative correlation between AKR1B10 expression and lipid synthesis, AKR1B10^{High} tumour cells must rely either on increased uptake of exogenous fatty acids or increased release from intracellular fatty acid stores. All three AKR1B10^{High} cell lines showed increased fatty acid uptake (Fig. 5b) whereas staining of intracellular neutral lipids with the lipophilic fluorescent dye BODIPY 493/503 revealed no significant difference in lipid droplet content between AKR1B10^{High} and AKR1B10^{Low} cells (Fig. 5c,d), indicating that AKR1B10^{High} cells predominantly fuel FAO via the uptake of free fatty acids.

AKR1B10 sustains FAO-dependent metastatic colonisation

The finding that increased AKR1B10 expression promotes metastatic colonisation of the lungs (Fig. 1 and Fig. 2d-f) and is associated with an increased dependency on FAO (Fig. 4) and enhanced tolerance of low glucose culture conditions (Fig. 3c-e) raises two important questions. First, what is the mechanism by which AKR1B10 modulates these activities? AKR1B10 is distinguished from the other well-characterised AKR1B subfamily member AKR1B1 by its increased catalytic activity for retinals, isoprenyl aldehydes and, importantly, for cytotoxic aldehydes such as 4-hydroxy-2-nonenal (4-HNE)²³. The latter is a toxic lipid peroxide by-product of the elevated reactive oxygen species (ROS) levels associated with oxidative stress. The interaction between FAO and ROS is complex. It is well documented that FAO, via its ability to generate NADPH, reduces ROS levels²⁶ but, conversely, it has been demonstrated that elevation of ROS in cells, for example as a result of loss of matrix attachment or treatment with rotenone or tumour necrosis factor- α , inhibits FAO^{27,28}. Consistent with the observation that AKR1B10^{Low} cells have reduced viability when cultured in LG DMEM (Fig. 3c-e), glucose deprivation resulted in elevated levels of lipid peroxidation as detected by BODIPY 581/591 C₁₁ fluorescence (Fig. 5e,f; Supplementary Figure 4). However, lipid peroxidation levels did not increase when AKR1B10^{High} cells were cultured in LG DMEM, suggesting that

in metabolically challenging conditions AKR1B10 functions to limit the toxicities associated with oxidative stress and maintain FAO activity.

Second, do these cellular mechanisms operate in physiologically relevant settings? To address this, 3D tumour spheroids were treated with the FAO inhibitor etomoxir. Etomoxir had no effect on growth of AKR1B10^{Low} tumour spheroids but inhibited the increased growth observed in the AKR1B10^{High} tumour spheroids (Fig. 6a). More importantly, mice were inoculated intravenously with MDA-MB-231-Luc AKR1B10^{High} or AKR1B10^{Low} cells and, after 7 days when the tumour cells will have extravasated into the lung tissue, treated with or without etomoxir. As previously shown (Fig. 2d), MDA-MB-231^{High} cells gave rise to a significantly increased lung tumour burden as monitored by *in vivo* IVIS imaging, *ex vivo* measurement of lung weight and quantification of metastatic burden (Fig. 6b) and this increased AKR1B10^{High} metastatic colonisation was effectively impaired by etomoxir treatment, with no effect of etomoxir on the metastatic growth of AKR1B10^{Low} cells.

Together these data support a model in which AKR1B10 functions to maintain FAO in tumour cells, particularly during metastatic colonisation of the pro-oxidative lung microenvironment².

Discussion

The data presented here demonstrates that *AKR1B10* expression is elevated in ER- and HER2+ breast cancers and that within these breast cancer subtypes, high *AKR1B10* expression is associated with an increased incidence of metastatic relapse at secondary sites. In contrast to previous reports^{29,30}, we find that AKR1B10^{High} breast cancer cells do not display altered survival or proliferation properties when cultured *in vitro* in full medium (Fig. 2c, Fig. 3c, Fig. 3e) or when grown as primary tumours in the fat pads of recipient mice (Fig. 1e). However, AKR1B10^{High} cells are more successful than AKR1B10^{Low} cells when cultured in nutrient poor conditions

such as in low glucose (Fig. 3c,d) or when colonising the lungs (Fig. 1d, Fig. 6b) and this is associated with an increased utilisation of FAO.

The ability to modulate metabolic characteristics is a feature of metastasising tumour cells as they adapt to the unique environments that they encounter^{1,2}. FAO, until recently relatively understudied in cancer, is a key source of ATP, NADH, NADPH and FADH₂ providing a survival advantage to tumour cells, particularly under challenging conditions such as hypoxia, nutrient stress or under therapeutic challenge^{31,32}. Moreover, by analysing multiple breast cancer clinical data sets, Camarda and colleagues have demonstrated dysregulation of fatty acid metabolism genes in triple negative (TN) compared to receptor positive breast cancers and, in particular, increased expression key activators of FAO, such as PGC-1 α (*PPARGC1A*) and decreased expression of genes encoding regulators of fatty acid synthesis³³, a pattern demonstrated here to be recapitulated in AKR1B10^{High} tumours. Although the role of PGC-1 α expression in metastasis is controversial³⁴, increased expression has been demonstrated to promote breast cancer metastasis in a variety of models systems³⁵⁻³⁷ and to be associated with increased FAO and an enhanced ability of cells to survive in 3D acini assays³¹. Conversely, impairment of FAO decreases cell survival in acini assays²⁷ and reduces tumour burden in the lungs and livers following intravenous inoculation³⁸. Here we demonstrate that AKR1B10^{High} cells fuel FAO by an increased uptake of exogenous fatty acids. To date, the best characterised fatty acid transporters are CD36, fatty acid translocase and low density lipoprotein receptor, and it is of particular interest is the recent identification of CD36^{bright} cells marking a population of metastasis-initiating cells³⁹, and that these cells display an upregulated FAO signature.

AKR1B10 belongs to the aldo-keto reductase (AKR) superfamily of NADP(H)-dependent enzymes⁴, and together with AKR1B1 and AKR1B15 form the AKR1B subfamily of enzymes characterised by their ability to reduce a variety of endogenous and xenobiotic aldehydes, dicarbonyl components and some drug ketones²³. The

AKR1B10 gene promoter contains both an activator protein-1 (AP-1) element and an antioxidant response element (ARE)⁴⁰ and *AKR1B10* expression can be regulated by AP1 downstream of IRAK1 or EGFR signalling^{41,42} and by NRF2 (nuclear factor erythroid 2-related factor 2) binding to the ARE element^{40,43}. Consistent with the latter, induction of oxidative stress results in NRF2-mediated upregulation of *AKR1B10* expression⁴⁴. The lungs, due to the high levels of oxygen and exposure to toxic compounds, are characterised by a high level of oxidative stress creating a challenging microenvironment for metastasising tumour cells². In addition, all metastasising tumour cells will experience oxidative stress particularly in the early stages of metastatic colonisation when they have yet to form stable cell:cell and cell:matrix attachments and nutrient deprivation^{1,45} and, in experimental models, successful metastasis is associated with metabolic changes that permit cells to withstand oxidative stress⁴⁶⁻⁴⁸. Pro-oxidative conditions result in elevated ROS production driving peroxidation of lipids that can then be degraded to reactive electrophilic lipid peroxidation products, which in turn can form covalent adducts in DNA, proteins and membrane lipids. Unchecked, these lipid peroxide breakdown products are highly damaging and cytotoxic to cells. Further, under such conditions where production of ATP via FAO would be desirable, these elevated ROS levels inhibit FAO^{27,28,31}. Interestingly, there is now increasing evidence that antioxidants, which inhibit ROS production, or loss of function mutations in *Keap1*, which result in hyperactivation of the NRF2-mediated endogenous antioxidant transcriptional programme, promote lung tumour progression and increase metastatic colonisation of melanomas⁴⁶⁻⁴⁹. These studies highlight the need for tumour cells in pro-oxidative environments to employ strategies to combat oxidative stress, and that this may be particularly pertinent for disseminated tumour cells that have yet to re-establish cell:cell and cell:matrix attachments^{27,50}. Via its ability to detoxify lipid peroxidation products by reduction of the carbonyl-groups to the corresponding alcohol metabolite^{8,51-53}, increased *AKR1B10* activity could serve to protect tumours cells

from oxidative stress-induced damage and cytotoxicity and permit maintained FAO activity. Certainly, elevated levels of FAO are associated with the increased metastasis of AKR1B10^{High} cells as treatment of mice with the FAO inhibitor etomoxir impairs the enhanced metastatic growth of AKR1B10^{High} cells whilst having no impact on AKR1B10^{Low} metastasis.

In conclusion, the experimental and clinical data presented support a role for AK1B10 in promoting metastasis of breast cancers functioning to support an altered metabolic program during secondary site colonisation. The findings raise the opportunity to use AKR1B10 expression to identify breast cancers patients with an increased risk of distant metastatic relapse, and further develop AKR1B10²³ and FAO³² inhibitors in the advanced breast cancer setting. This is particularly pertinent given that ER- breast cancer patients in general have a poorer prognosis and limited therapeutic options, making appropriate stratification for targeted therapies to control disease burden of paramount importance.

Methods

All animal work was carried out under UK Home Office Project licenses 70/7413 and P6AB1448A (Establishment License, X702B0E74 70/2902) and was approved by the Animal Welfare and Ethical Review Body at The Institute of Cancer Research. All animals were monitored on a daily basis by staff from the ICR Biological Service Unit for signs of ill health.

Cells

4T1 cells were obtained from ATCC in 2013 and transduced with firefly luciferase lentiviral expression particles (Amsbio, LVP326) to generate 4T1-Luc cells. HEK293 cells and human breast cancer cell lines (MDA-MB-231, MDA-MB-453, MDA-MB-468, BT20, HCC38, HCC1395) were obtained from ATCC, and MDA-MB-231-Luc from (SibTech Inc.) between 2005 and 2012 and short tandem repeat tested every 4 months (StemElite ID System; Promega). Subtype assessment using the absolute assignment of breast cancer intrinsic molecular subtype (AIMS) assigned MDA-MB-231 and HCC1395 cells as 100% probability of basal-like and MDA-MB-453 cells as a 100% probability of HER2-enriched. All cell lines were used within 10 passages after resuscitation and were routinely subject to mycoplasma testing. HCC1395 cells were cultured in Roswell Park Memorial Institute (RPMI) medium. All other cell lines were cultured in Dulbecco's Modified Eagle's Medium (DMEM). Culture media were supplemented with 10% foetal bovine serum (FBS; Invitrogen), 50 U mL⁻¹ penicillin and 50 U mL⁻¹ streptomycin. Where indicated cells were cultured in full DMEM (4.5 g L⁻¹ D-glucose) or low glucose (LG) DMEM (1 g L⁻¹ D-glucose).

4T1-Luc cells were transduced with Mission shRNA lentiviral particles (Supplementary Table 2) at multiplicity of infection of 5. Stably transduced cells were selected in 2.5 µg mL⁻¹ puromycin. HCC1395 cells were transduced with GIPZ shRNA lentiviruses (Dharmacon; SupplementaryTable 3), selected in 2.5 µg mL⁻¹ puromycin and FACSorted for GFP positive cells. For ectopic expression of

AKR1B10, MDA-MB-231 and MDA-MB-453 cells, cells were transduced with empty vector or AKR1B10 pReceiver-Lv156 lentivirus (Genecopoeia; Supplementary Table 3) and selected in $2.5 \mu\text{g mL}^{-1}$ puromycin. The cells were cultured for an additional 3 passages in selective medium to enrich the infected cell population.

In vivo shRNA screen

As previously detailed⁵⁴ the screen was performed with 4T1-Luc cells transduced in 24 subpools (each subpool containing 96 shRNAs) with the miR-30–based shRNA library targeting the Cancer 1000 mouse gene set⁵⁵ and inoculated intravenously into female BALB/c mice. On day 21, lungs were removed at necropsy and gDNA extracted from preinoculation cell pellets and tumour bearing lungs. shRNA representation in the original library plasmid DNA, preinoculation 4T1-Luc cells and 4 independent metastatic lung samples (samples A - D) per subpool was assessed by next generation sequencing (Fig. 1a).

shRNA representation in the preinoculation 4T1-Luc cells was compared to the representation in the 4 lung samples. Hits were defined as shRNAs that had decreased representation (Z-score >-2) in ≥ 3 lung samples compared to the preinoculation cells and had no significant effect on viability when comparing shRNA representation in the plasmid pool to the preinoculation cells.

In vivo studies

6-8 week old female BALB/c or BALB/c Nude (CAnN-Cg-Foxn1^{nu}/Crl) mice were purchased from Charles River. For experimental lung metastasis assays, 1×10^5 4T1 or 1×10^6 MDA-MB-231 cells in $100 \mu\text{L}$ PBS were injected via the lateral tail vein. Where indicated, mice were randomised into 2 groups on day 7 and treated with etomoxir (Tocris) at 40 mg kg^{-1} or vehicle (water) intraperitoneally every other day. At termination, lungs were IVIS imaged *ex vivo*, weighed, formalin-fixed and paraffin-embedded. $3-4 \mu\text{m}$ thick sections were cut and stained with haematoxylin and eosin

(H&E). Total number of individual nodules was counted manually in 3-4 lung sections, approximately 150 μm apart, per animal. Where indicated, lung metastatic area was quantified as the mean percentage of the area of the metastatic nodules normalised to the total lung area. For spontaneous metastasis assays, 1×10^4 4T1-Luc cells in 50 μL PBS were injected into the 4th mammary fat pad of female BALB/c mice. Tumour growth was measured twice a week using callipers up to a maximum diameter of 17 mm. Tumour volume was calculated using the following formula: $\text{Volume} = 0.5236 \times \text{diameter}^3$. At the end of the experiment, orthotopic tumours and lungs were harvested at necropsy. Where indicated, 300 μL arterial blood was isolated by cardiac puncture and 50 μL per well plated in DMEM plus 10% FCS in a 6-well plate per mouse. Tumour cell colonies were stained 14 days later with crystal violet. Plates were scanned at 300 dpi on EpsonV700 scanner and total number of colonies counted per mouse.

For lung retention assays, 4T1-Luc shNTC and shAkr1b8-4 cells were labelled with CellTracker Red CMTPX or Green CMFDA dyes (Molecular Probes), trypsinised, mixed at a 1:1 ratio and a total of 0.7×10^6 cells injected intravenously into BALB/c mice. Mice were sacrificed at 1 and 16 hours post injection and 6 images per lung taken on a Zeiss LSM 710 microscope (x20 lens). Tumour cell colonisation within the lung was quantified in Fiji, by converting red and green images into separate binary images and measuring total tumour cell coverage per field of view. Alternatively, 1×10^6 MDA-MB-231-Luc cells were injected intravenously into BALB/c Nude mice. Mice were sacrificed at 1 and 8 hours post injection and lung sections stained for human lamin A/C. Number of lamin A/C positive cells were quantified using Fiji in whole lung sections.

Metabolic assays

For all assays, 1.5×10^4 (MDA-MB-453) or 2.0×10^4 (HCC1395, MDA-MB-231) cells were seeded in XF96 cell culture plates incubated in a 5% CO_2 incubator at

37°C overnight and results were normalised to cell number using CyQuant DNA staining (ThermoFisher).

Seahorse XF Glycolysis Stress Test. Culture medium was replaced with 175 µL pH 7.4 ±0.1 bicarbonate-free DMEM supplemented with 2 mM L-glutamine, and the plate incubated at 37°C for 1 hour in a non-CO₂ incubator. ECAR was measured using the Seahorse XF Glycolysis Stress Test Kit (Agilent) on an XFe96 Analyzer. Final concentrations of 10 mM glucose, 2 µM oligomycin and 100 mM 2-deoxyglucose (2-DG) were used for all conditions. Glycolysis, glycolytic capacity and glycolytic reserve were calculated as follows:

Glycolysis = (maximum rate measurement before oligomycin injection) - (final rate measurement before 2-DG injection)

Glycolytic capacity = (maximum rate measurement after oligomycin injection) - (final rate measurement before glucose injection)

Glycolytic reserve = (glycolytic capacity) - (glycolysis)

Seahorse XF Mito Fuel Flex Test. Culture medium was replaced with 180 µL pH 7.4 ±0.1 bicarbonate-free DMEM supplemented with 10 mM glucose, 1 mM sodium pyruvate and 2 mM L-glutamine, and the plate incubated at 37°C for 1 hour in a non-CO₂ incubator. OCR was measured using the Seahorse XF Mito Fuel Flex Test Kit (Agilent) on an XFe96 Analyzer. In the Mito Fuel Flex Test the import of three major metabolic substrates, fatty acids, glutamine and/or pyruvate is inhibited using etomoxir (4 µM), BPTES (3 µM) and UK5099 (2 µM), respectively. To measure dependency on FAO, OCR is measured at baseline, following injection of etomoxir (Treatment 1) and following injection of BPTES and UK5099 (Treatment 2). To measure dependency on glutamine oxidation, OCR is measured at baseline, following injection of BPTES and following injection of etomoxir and UK5099.

Dependency was calculated with the following formula. Dependency (%) = [(baseline OCR - Target 1 inhibitor OCR)/(Baseline OCR - All 3 inhibitor OCR)] x 100.

Palmitate-BSA FAO assay. Culture media was replaced with 175 μ L of pH 7.4 \pm 0.1 Krebs-Henseleit Buffer (111 mM NaCl, 4.7 mM KCl, 1.25 mM CaCl₂, 2 mM MgSO₄, 1.2 mM NaH₂PO₄) supplemented with 2.5 mM glucose, 0.5 mM carnitine and 5 mM HEPES, and the plate was incubated at 37°C for 1 hour in a non-CO₂ incubator. 30 μ L of 1 mM palmitate-BSA substrate (Agilent) was loaded directly into port A of a Seahorse loading sensor cartridge. OCR was measured at baseline and following palmitate-BSA addition on an XFe96 Analyzer. Levels of FAO are calculated as follows: Change in OCR (Δ OCR) = (OCR following palmitate-BSA addition - OCR at baseline).

Cell based assays

Colony formation assay. 0.2-5x10⁴ cells were seeded per well in a 6-well plate. 7-10 days post seeding, plates were stained with crystal violet, dried and scanned at 1200 dpi using the GelCount colony counter system. Images were analysed using Fiji.

Cell viability assay. 1x10² cells in 100 μ L medium were seeded per well in a 96-well plate and incubated at 37°C. Immediately after seeding, and every 24 hours afterwards, cells viability was analysed by CellTiter-Glo (Promega). Fold change was calculated relative to the plate read at seeding (time 0). For 3D viability assays, 5x10³ cells were seeded into ultra-low adherence U-bottomed 96-well plates (Corning). On day 6 tumour spheroids were lysed in CellTiter-Glo for 30 minutes and viability analysed using a Victor X5 plate reader. Where indicated, etomoxir (200 μ M) or vehicle (DMSO) was added 24 hours after seeding.

2D cell growth. 1x10³ cells were seeded per well in a 96-well plate and subject to live cell imaging (IncuCyte S3 - Essen Bioscience) every 12 hours for 4.5

days. Phase contrast images were collected, a confluence mask applied to the segmented images and analysed using IncuCyte integrated confluence algorithm).

Anoikis assay. 5×10^4 cells per well were seeded into low-adherence 6-well plates (Costar) in DMEM containing 2% FBS. At 24 hours post-seeding, cells were stained with Annexin V-APC/PI Apoptosis Detection Kit (eBioscience) and analysed using a BD Biosciences LSRII flow cytometer with FACSDIVA and FlowJo software. Cell viability was measured as a proportion of healthy (Annexin-negative, PI-negative) cells.

Glucose uptake assay. $1-5 \times 10^4$ cells were seeded in 100 μ L culture medium containing 10% FBS into a 96-well plate and incubated for 24 hours at 37°C. Cells were washed twice with PBS before the Glucose Uptake-Glo assay (Promega) was performed according to the manufacturer's protocol.

Fatty acid uptake assay. $1-3 \times 10^4$ cells were seeded in 100 μ L culture medium containing 10% FBS into a 96-well plate and incubated for 24 hours at 37°C. Cells were washed and serum deprived for 1 hour before 100 μ L Free Fatty Acid solution (Abcam). After incubating the cells for 1 hour at 37°C the fluorescence signal was measured using a fluorescence microplate reader at Ex/Em = 485/515 nm.

Lipid synthesis assay. Cells were incubated for 4 hours in medium containing 10 μ Ci mL⁻¹ [1-¹⁴C] acetic acid, lysed in 0.5% Triton X-100 and lipids extracted by successive addition of 2 mL methanol, 2 mL chloroform, and 1 mL H₂O. Phases were separated by centrifugation at 1000g for 15 minutes. The organic (lower) phase was recovered and dried overnight. Lipids were dissolved in Ultima Gold LSC Cocktail and counted on a scintillation counter.

Lipid droplet analysis. 7.5×10^3 cells were seeded on coverslips in medium DMEM plus 10% FBS. 24 hour post seeding cells were serum-starved for 1 hour, stained for 10 min with BODIPY 493/503 dye (D3922, Molecular Probes) and DAPI (Molecular Probes), and imaged on a Leica SP2 confocal microscope. Images were

analysed using basic algorithms in the Columbus analysis software package (PerkinElmer) with lipid droplets quantified using the spot finder application.

For lipid peroxidation analysis cells cultured for 48 hours in DMEM or LG DMEM plus 10% FBS, stained for 30 min with 1 $\mu\text{g mL}^{-1}$ BODIPY 581/591 C11 (D3861, Molecular Probes) and DAPI and imaged on a Leica SP2 confocal microscope. Images were analysed using basic algorithms in the CellProfiler software package (cellprofiler.org) to quantify oxidised (green) and non-oxidised (red) BODIPY probe.

Antibodies, and the dilutions used, are detailed in Supplementary Table 4.

Analysis of human datasets

Series matrix files for TCGA 522 primary breast cancer samples and a neoadjuvant chemotherapy-treated invasive breast cancer clinical cohort (Hatzis, accession code GSE25066)²⁴ were downloaded from [https://tcga-data.nci.nih.gov/docs/publications/brca_2012/] and the Gene Expression Omnibus (GEO) site, respectively. Intrinsic molecular subtypes and clinical receptor status of ER, PGR, and HER2 were retrieved from the supplemental tables of the corresponding publications. In the Tukey boxplots, box indicates the ends of the 1st and 3rd quartiles, bar indicates median, whiskers indicated 1.5 IQR (interquartile range), and dots indicate outliers. Clinical relevance of variable *AKR1B10* expression was assessed using publicly available data from Gyorffy *et al.*²². Unless otherwise stated, for Kaplan-Meier analysis the highest quartile of gene expression was used to dichotomise the breast cancers. For association of *AKRB10* expression and FAO pathway activity, a mouse FAO gene set was obtained from [<http://www.informatics.jax.org/go/term/GO:0019395>]. Human orthologues of the 88 (FAO88) genes were identified using [<http://www.informatics.jax.org/homology.shtml>]. In Hatzis dataset, Affymetrix Human Genome U133A Array annotation file (GEO accession code GPL96) was used to map the symbol to the corresponding Affymetrix

Probe_Set_ID. When multiple Probe_Set_IDs mapped to the same symbol, the Probe_Set_ID with the highest variance across samples was selected to represent the gene. Genes were discarded from further analysis if they were not mapped to either the annotation file or the expression data. FAO88 score was calculated as a mean of the normalised Log2-expression of the matched individual genes within the FAO88. Pearson correlation was used to assess associations between *AKR1B10* expression and this FAO88 score of the samples in each subset. *AKR1B10* expression in human cell lines was assessed in the dataset of Neve and colleagues (ArrayExpress with accession number E-TABM-157).

Statistical analysis

Statistics were performed using GraphPad Prism 7. Unless stated otherwise, all numerical data is expressed as the mean \pm standard deviation (SD) for *in vitro* assays and \pm standard error of mean (SEM) for *in vivo* tests. Comparisons between 2 groups were made using the two-tailed, unpaired Student's *t*-test. For experiments with two control groups (e.g. shNTC and shCTRL groups) and two experimental groups (e.g. shAkr1b8-4 and shAkr1b8-7 groups) comparisons between an individual control and an individual experimental group were made using one-way analysis of variance (ANOVA) followed by the two-stage step-up method of Benjamini, Krieger and Yekutieli. Comparisons between multiple groups with independent variables were made using two-way ANOVA with Bonferroni post-testing, with a confidence interval of 95% for individual comparisons. To determine false discovery rates (FDR) in breast cancer datasets, the Pearson correlation *P* values were adjusted using the Benjamini-Hochberg method for multiple comparisons in each independent breast cancer clinical cohort. Statistical significance was defined as: *, *P*<0.05; **, *P*<0.01; ***, *P*<0.001; ns, not significant.

Acknowledgements

This work was funded by Breast Cancer Now (CTR-Q4-Y3), working in partnership with Walk the Walk to CMI. NK is supported by an Institute of Cancer Research studentship. The GP laboratory is supported by the Institute of Cancer Research and a Cancer Research UK Grand Challenge award (C59824/A25044). We acknowledge NHS funding to the NIHR Biomedical Research Centre at The Royal Marsden and the ICR. The results published here are in whole or part based upon data generated by the TCGA Research Network [<http://cancergenome.nih.gov/>]. We thank Syed Haider and his team in the Breast Cancer Now Toby Robins Research Centre Bioinformatics Core Facility, the Breast Cancer Now Toby Robins Research Centre Nina Barough Pathology Core Facility and ICR FACS and Light Microscopy Facility for support in this project. We thank Andrea Morandi (University of Florence) and Frances Turrell for reading drafts of the manuscript, David Vicente and Rebecca Orha for technical assistance and David Robertson, Adam Tyson and Alexis Barr for help with the image analysis.

Competing interests

The authors declare no competing interests

Authors' contribution

Experimental data was generated by AvW, NK, MI, MA and UJ. Bioinformatics analysis was performed by QG. AvW, MI, GP, UJ and CMI devised and oversaw the project. AvW, MI, UJ and CMI wrote the manuscript with input from all other authors. GP and CMI acquired the funding.

Data availability

Details of the datasets analysed in this study are included in the section of Analysis of human datasets. The source data (uncropped immunoblots) underlying Fig. 2b are provided as Source Data File 1.

References

- 1 Lehoude, C., Dupuy, F., Rabinovitch, R., Jones, R. G. & Siegel, P. M. Metabolic Plasticity as a Determinant of Tumor Growth and Metastasis. *Cancer research* **76**, 5201-5208, doi:10.1158/0008-5472.CAN-16-0266 (2016).
- 2 Schild, T., Low, V., Blenis, J. & Gomes, A. P. Unique Metabolic Adaptations Dictate Distal Organ-Specific Metastatic Colonization. *Cancer cell* **33**, 347-354, doi:10.1016/j.ccell.2018.02.001 (2018).
- 3 Joshi, A., Rajput, S., Wang, C., Ma, J. & Cao, D. Murine aldo-keto reductase family 1 subfamily B: identification of AKR1B8 as an ortholog of human AKR1B10. *Biol Chem* **391**, 1371-1378, doi:10.1515/BC.2010.144 (2010).
- 4 Penning, T. M. The aldo-keto reductases (AKRs): Overview. *Chemico-biological interactions* **234**, 236-246, doi:10.1016/j.cbi.2014.09.024 (2015).
- 5 Gallego, O. *et al.* Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10. *Proceedings of the National Academy of Sciences of the United States of America* **104**, 20764-20769, doi:10.1073/pnas.0705659105 (2007).
- 6 Porte, S. *et al.* Aldo-keto reductases in retinoid metabolism: search for substrate specificity and inhibitor selectivity. *Chemico-biological interactions* **202**, 186-194, doi:10.1016/j.cbi.2012.11.014 (2013).
- 7 Endo, S. *et al.* Selective inhibition of the tumor marker AKR1B10 by antiinflammatory N-phenylanthranilic acids and glycyrrhetic acid. *Biol Pharm Bull* **33**, 886-890 (2010).
- 8 Martin, H. J. & Maser, E. Role of human aldo-keto-reductase AKR1B10 in the protection against toxic aldehydes. *Chemico-biological interactions* **178**, 145-150, doi:10.1016/j.cbi.2008.10.021 (2009).

- 9 Jin, J. *et al.* Aldo-keto Reductase Family 1 Member B 10 Mediates Liver Cancer Cell Proliferation through Sphingosine-1-Phosphate. *Sci Rep* **6**, 22746, doi:10.1038/srep22746 (2016).
- 10 Matkowskyj, K. A. *et al.* Aldoketoreductase family 1B10 (AKR1B10) as a biomarker to distinguish hepatocellular carcinoma from benign liver lesions. *Hum Pathol* **45**, 834-843, doi:10.1016/j.humpath.2013.12.002 (2014).
- 11 Fukumoto, S. *et al.* Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas. *Clinical cancer research : an official journal of the American Association for Cancer Research* **11**, 1776-1785, doi:10.1158/1078-0432.CCR-04-1238 (2005).
- 12 Chung, Y. T. *et al.* Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma. *Mod Pathol* **25**, 758-766, doi:10.1038/modpathol.2011.191 (2012).
- 13 Ma, J. *et al.* AKR1B10 overexpression in breast cancer: association with tumor size, lymph node metastasis and patient survival and its potential as a novel serum marker. *Int J Cancer* **131**, E862-871, doi:10.1002/ijc.27618 (2012).
- 14 Reddy, K. A. *et al.* Overexpression and enhanced specific activity of aldoketo reductases (AKR1B1 & AKR1B10) in human breast cancers. *Breast* **31**, 137-143, doi:10.1016/j.breast.2016.11.003 (2017).
- 15 Avgustinova, A. *et al.* Tumour cell-derived Wnt7a recruits and activates fibroblasts to promote tumour aggressiveness. *Nature communications* **7**, 10305, doi:10.1038/ncomms10305 (2016).
- 16 Deryugina, E. I. & Quigley, J. P. Matrix metalloproteinases and tumor metastasis. *Cancer metastasis reviews* **25**, 9-34, doi:10.1007/s10555-006-7886-9 (2006).

- 17 Rochefort, H., Capony, F. & Garcia, M. Cathepsin D: a protease involved in breast cancer metastasis. *Cancer metastasis reviews* **9**, 321-331 (1990).
- 18 Christopoulos, P. F., Msaouel, P. & Koutsilieris, M. The role of the insulin-like growth factor-1 system in breast cancer. *Molecular cancer* **14**, 43, doi:10.1186/s12943-015-0291-7 (2015).
- 19 Ho-Yen, C. M., Jones, J. L. & Kermorgant, S. The clinical and functional significance of c-Met in breast cancer: a review. *Breast Cancer Res* **17**, 52, doi:10.1186/s13058-015-0547-6 (2015).
- 20 Li, Z. *et al.* Overexpression of Aldo-keto reductase family 1 B10 protein in ductal carcinoma in situ of the breast correlates with HER2 positivity. *Cancer Biomark* **13**, 181-192, doi:10.3233/CBM-130337 (2013).
- 21 Neve, R. M. *et al.* A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. *Cancer cell* **10**, 515-527, doi:10.1016/j.ccr.2006.10.008 (2006).
- 22 Györffy, B. *et al.* An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. *Breast cancer research and treatment* **123**, 725-731, doi:10.1007/s10549-009-0674-9 (2010).
- 23 Matsunaga, T. *et al.* Aldo-Keto Reductase 1B10 and Its Role in Proliferation Capacity of Drug-Resistant Cancers. *Frontiers in pharmacology* **3**, 5, doi:10.3389/fphar.2012.00005 (2012).
- 24 Hatzis, C. *et al.* A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. *JAMA* **305**, 1873-1881, doi:10.1001/jama.2011.593 (2011).
- 25 Rohrig, F. & Schulze, A. The multifaceted roles of fatty acid synthesis in cancer. *Nature reviews. Cancer* **16**, 732-749, doi:10.1038/nrc.2016.89 (2016).

- 26 Panieri, E. & Santoro, M. M. ROS homeostasis and metabolism: a dangerous liason in cancer cells. *Cell death & disease* **7**, e2253, doi:10.1038/cddis.2016.105 (2016).
- 27 Schafer, Z. T. *et al.* Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. *Nature* **461**, 109-113, doi:10.1038/nature08268 (2009).
- 28 Setoyama, D., Fujimura, Y. & Miura, D. Metabolomics reveals that carnitine palmitoyltransferase-1 is a novel target for oxidative inactivation in human cells. *Genes Cells* **18**, 1107-1119, doi:10.1111/gtc.12098 (2013).
- 29 Huang, C. *et al.* AKR1B10 promotes breast cancer metastasis through integrin alpha5/delta-catenin mediated FAK/Src/Rac1 signaling pathway. *Oncotarget* **7**, 43779-43791, doi:10.18632/oncotarget.9672 (2016).
- 30 Li, J. *et al.* AKR1B10 promotes breast cancer cell migration and invasion via activation of ERK signaling. *Oncotarget* **8**, 33694-33703, doi:10.18632/oncotarget.16624 (2017).
- 31 Carracedo, A., Cantley, L. C. & Pandolfi, P. P. Cancer metabolism: fatty acid oxidation in the limelight. *Nature reviews. Cancer* **13**, 227-232, doi:10.1038/nrc3483 (2013).
- 32 Qu, Q., Zeng, F., Liu, X., Wang, Q. J. & Deng, F. Fatty acid oxidation and carnitine palmitoyltransferase I: emerging therapeutic targets in cancer. *Cell death & disease* **7**, e2226, doi:10.1038/cddis.2016.132 (2016).
- 33 Camarda, R. *et al.* Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. *Nature medicine* **22**, 427-432, doi:10.1038/nm.4055 (2016).
- 34 Gravel, S. P. Deciphering the Dichotomous Effects of PGC-1alpha on Tumorigenesis and Metastasis. *Front Oncol* **8**, 75, doi:10.3389/fonc.2018.00075 (2018).

- 35 Andrzejewski, S. *et al.* PGC-1alpha Promotes Breast Cancer Metastasis and Confers Bioenergetic Flexibility against Metabolic Drugs. *Cell metabolism* **26**, 778-787 e775, doi:10.1016/j.cmet.2017.09.006 (2017).
- 36 Carracedo, A. *et al.* A metabolic prosurvival role for PML in breast cancer. *The Journal of clinical investigation* **122**, 3088-3100, doi:10.1172/JCI62129 (2012).
- 37 LeBleu, V. S. *et al.* PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. *Nature cell biology* **16**, 992-1003, 1001-1015, doi:10.1038/ncb3039 (2014).
- 38 Park, J. H. *et al.* Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer. *Cell Rep* **14**, 2154-2165, doi:10.1016/j.celrep.2016.02.004 (2016).
- 39 Pascual, G. *et al.* Targeting metastasis-initiating cells through the fatty acid receptor CD36. *Nature* **541**, 41-45, doi:10.1038/nature20791 (2017).
- 40 Nishinaka, T. *et al.* Regulation of aldo-keto reductase AKR1B10 gene expression: involvement of transcription factor Nrf2. *Chemico-biological interactions* **191**, 185-191, doi:10.1016/j.cbi.2011.01.026 (2011).
- 41 Cheng, B. Y. *et al.* IRAK1 Augments Cancer Stemness and Drug Resistance via the AP-1/AKR1B10 Signaling Cascade in Hepatocellular Carcinoma. *Cancer research* **78**, 2332-2342, doi:10.1158/0008-5472.CAN-17-2445 (2018).
- 42 Liu, Z. *et al.* Epidermal growth factor induces tumour marker AKR1B10 expression through activator protein-1 signalling in hepatocellular carcinoma cells. *Biochem J* **442**, 273-282, doi:10.1042/BJ20111322 (2012).
- 43 Ooi, A. *et al.* An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. *Cancer cell* **20**, 511-523, doi:10.1016/j.ccr.2011.08.024 (2011).

- 44 Ebert, B., Kisiela, M., Wsol, V. & Maser, E. Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29. *Chemico-biological interactions* **191**, 239-249, doi:10.1016/j.cbi.2010.12.026 (2011).
- 45 Gill, J. G., Piskounova, E. & Morrison, S. J. Cancer, Oxidative Stress, and Metastasis. *Cold Spring Harb Symp Quant Biol* **81**, 163-175, doi:10.1101/sqb.2016.81.030791 (2016).
- 46 Le Gal, K. *et al.* Antioxidants can increase melanoma metastasis in mice. *Sci Transl Med* **7**, 308re308, doi:10.1126/scitranslmed.aad3740 (2015).
- 47 Piskounova, E. *et al.* Oxidative stress inhibits distant metastasis by human melanoma cells. *Nature* **527**, 186-191, doi:10.1038/nature15726 (2015).
- 48 Sayin, V. I. *et al.* Antioxidants accelerate lung cancer progression in mice. *Sci Transl Med* **6**, 221ra215, doi:10.1126/scitranslmed.3007653 (2014).
- 49 Romero, R. *et al.* Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. *Nature medicine* **23**, 1362-1368, doi:10.1038/nm.4407 (2017).
- 50 Hawk, M. A. & Schafer, Z. T. Mechanisms of redox metabolism and cancer cell survival during extracellular matrix detachment. *The Journal of biological chemistry* **293**, 7531-7537, doi:10.1074/jbc.TM117.000260 (2018).
- 51 Matsunaga, T. *et al.* Aldo-keto reductase 1B10 promotes development of cisplatin resistance in gastrointestinal cancer cells through down-regulating peroxisome proliferator-activated receptor-gamma-dependent mechanism. *Chemico-biological interactions* **256**, 142-153, doi:10.1016/j.cbi.2016.07.008 (2016).
- 52 Shen, Y., Zhong, L., Johnson, S. & Cao, D. Human aldo-keto reductases 1B1 and 1B10: a comparative study on their enzyme activity toward electrophilic carbonyl compounds. *Chemico-biological interactions* **191**, 192-198, doi:10.1016/j.cbi.2011.02.004 (2011).

- 53 Zhong, L. *et al.* Aldo-keto reductase family 1 B10 protein detoxifies dietary and lipid-derived alpha, beta-unsaturated carbonyls at physiological levels. *Biochem Biophys Res Commun* **387**, 245-250, doi:10.1016/j.bbrc.2009.06.123 (2009).
- 54 Ashenden, M. *et al.* An In Vivo Functional Screen Identifies JNK Signaling As a Modulator of Chemotherapeutic Response in Breast Cancer. *Molecular cancer therapeutics* **16**, 1967-1978, doi:10.1158/1535-7163.MCT-16-0731 (2017).
- 55 Dickins, R. A. *et al.* Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. *Nature genetics* **37**, 1289-1295, doi:10.1038/ng1651 (2005).

Figure Legends

Fig. 1 | *Akr1b8* as a metastasis enhancer *in vivo*. **a**, shRNA abundance was assessed in the shRNA plasmid library, shRNA transduced preinoculation cells and 4 tumour-bearing lungs samples (Samples A - D). **b**, Median Z-scores for shRNA representation in the tumour-bearing lung samples compared to 4T1-Luc preinoculation cells, identifying 109 significantly enriched (Z-score >2) and 81 significantly depleted (Z-score <-2) shRNAs. **c**, Shortlist of 23 putative metastasis enhancers identified in the screen. **d**, 1×10^5 4T1-Luc transduced with two independent shRNA lentiviruses targeting *Akr1b8* (shAkr1b8-4, shAkr1b8-7), a non-targeting shRNA (shNTC) or a control shRNA (shCTRL) were injected intravenously into BALB/c mice (n=6 per group). Lung tumour burden was assessed at the end of the experiment (day 12) by *ex vivo* IVIS imaging (average radiance \pm SEM; dashed line indicates mean radiance of aged-matched non-tumour bearing mice), *ex vivo* lung weight \pm SEM, and quantifying % tumour area per lung section \pm SEM. Representative lung sections, arrowheads indicating tumour nodules. Scale bar, 1 mm. **e**, 1×10^4 4T1-Luc cells were injected orthotopically into BALB/c mice (n=11-12 mice per group). Animals were sacrificed on day 33. Final, tumour volume, ns for all groups except shNTC vs. shAkr1b8-7 ($P=0.005$), two-way ANOVA with Tukey's multiple comparison test. Tumour weight \pm SEM at necropsy. Number of lung metastases per mouse \pm SEM. Representative lung images are shown in Supplementary Fig. 2. **f**, From the experiment shown in panel e, quantification of mean tumour cell colonies derived from circulating tumour cells in 300 μ L arterial blood per mouse \pm SEM, ns for all groups. **g**, 4T1-Luc anoikis assay, n=3, mean \pm SD. **h**, Left panels, shNTC- and shAkr1b8-4 4T1-Luc cells were labelled with CellTracker red or green dyes, respectively, inoculated intravenously into BALB/c mice. 1 and 16 hours after inoculation, lungs were extracted and imaged. Data shown are mean tumour cell coverage per field of view, n=4 mice per group per time point \pm SEM.

Scale bar, 100 μ m. Right panels, equivalent results were obtained in a dye swap experiment. ns, not significant; *, $P<0.05$; **, $P<0.01$; ***, $P<0.001$; one-way ANOVA followed by two-stage step-up method of Benjamini, Krieger and Yekutieli (**d-f**), unpaired t -test (**g-h**).

Fig. 2 | AKR1B10 is associated with increased risk of distant metastatic relapse. **a**, Tukey boxplots of *AKR1B10* expression (Log_2 median-centred values) in the TCGA breast cancer dataset based on intrinsic subtype (one-way ANOVA with Tukey's multiple comparison test) or receptor status (t -test with Welch's correction). Numbers of samples in each category are indicated; *, $P<0.05$; ***, $P<0.001$. **b**, *AKR1B10* western blot in human breast cancer cell lines (upper panel). Lower panel, *AKR1B10* expression in shNTC (*AKR1B10*^{High}) or sh*AKR1B10* (*AKR1B10*^{Low}) HCC1395 cells and in MDA-MB-231 cells and MDA-MB-453 cells transduced with vector-alone (*AKR1B10*^{Low}) or ectopically expressing *AKR1B10* (*AKR1B10*^{High}). Molecular size markers are in kDa. Source blots are provided as Source Data File 1. **c**, Colony formation assay comparing *AKR1B10*^{High} and *AKR1B10*^{Low} cells, $n=3$ per sample \pm SD. **d**, 5×10^4 MDA-MB-231 cells expressing vector alone (Vec) or with ectopic expression of *AKR1B10* were cultured in 6-well low-adherence plates in 2% FBS for 24 h before annexin V and PI staining. Data shown as percent of non-apoptotic (annexin V-, PI-) cells remaining. $n=3$, mean \pm SD. **e**, 1×10^6 MDA-MB-231 cells were injected intravenously in BALB/c Nude mice. Mice were sacrificed at 1 or 8 hours ($n=3$ per group per time point) and lung sections stained for human lamin A/C. Data shown is cell number per $\text{cm}^2 \pm$ SEM. Representative images, scale bar, 0.5 mm. ns, not significant; unpaired t -test (**c-e**). **f**, Kaplan-Meier analysis of distant metastasis-free survival (DMFS) of all ($n=1746$), ER+ ($n=664$), ER- (218) or HER2+ ($n=126$) patients in the Györffy *et al.*,²² dataset. Hazard ratios (HR) and log-rank Mantel-Cox P -values are shown.

Fig. 3 | AKR1B10^{High} cells have decreased glycolysis and increased tolerance of low glucose conditions. In all experiments AKR1B10^{Low} and AKR1B10^{High} cells are shown in pale and dark blue, respectively. **a**, Glycolytic function assessed using the Seahorse XF Glycolysis Stress test. Glycolysis was determined following glucose (10 mM) injection and glycolytic capacity was determined after oligomycin (2 μ M) injection. Glycolytic reserve was measured as the difference between the glycolytic capacity and glycolysis. Left panel, representative extracellular acidification rate (ECAR) profile for HCC1395 AKR1B10^{Low} and AKR1B10^{High} cells. Right panel, quantification of glycolytic function (shNTC, n=6; shAKR1B10 n=5) \pm SD. **b**, Glucose Uptake-Glo assay (see Methods). n=4 per sample \pm SD. **c**, 1×10^3 MDA-MB-231 or 5×10^3 MDA-MB-453 cells seeded into 96-well plate in DMEM or low glucose (LG) (1 g L^{-1}) DMEM and live imaged over 4.5 days (Incucyte S3). n=10 per condition normalised to day 0 \pm SD; ***, $P < 0.001$ two-way ANOVA with Bonferroni post-testing. **d**, 5×10^3 cells seeded into U-bottomed plates in LG DMEM (n=10). Tumour spheroid viability analysed using CellTiter-Glo on day 6 \pm SD. Equivalent results were obtained in two independent experiments. **e**, 2×10^3 MDA-MB-231 cells were seeded into a 6-well plate (n=3 wells per condition) and cultured in the presence of 4.5, 2.5 or 1 g L^{-1} D-glucose. Data represents cell area from 3 independent experiments \pm SD. ns, not significant; *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$, unpaired t -test (**a,b,d,e**).

Fig. 4 | Fatty acid oxidation in AKR1B10^{High} cells and breast tumours. **a**, Dependency of cells on glutamine (left panel) and fatty acid (right panel) oxidation monitored using the Mito Fuel Flex test (see Methods). HCC1395 and MDA-MB-231, n=8 \pm SD; MDA-MB-453, n=3-4 \pm SD. **b**, Change in OCR (Δ OCR) following palmitate-BSA addition calculated as (OCR at the time of palmitate-BSA injection - final basal OCR). n=3 \pm SD. **c**, Pearson correlation of AKR1B10 expression and FAO88 score in triple negative (TN), ER- and HER2-enriched, ER+ and all breast cancers in the TCGA and Hatzis *et al.*²⁴ datasets. To determine false discovery rates (FDR), the

Pearson correlation *P* values were adjusted using the Benjamini-Hochberg method for multiple comparisons in each independent breast cancer clinical cohort. ns, not significant; *, *P*<0.05; **, *P*<0.01; ***, *P*<0.001, unpaired *t*-test (**a-b**).

Fig. 5 | AKR1B10 limits lipid peroxidation. **a**, ¹⁴C-acetate incorporated into lipids. Data from 3 independent experiments relative to AKR1B10^{Low} cells. **b**, Fatty acid uptake. *n*=5 ±SD. **c**, HCC1395 and **d**, MDA-MB-231 cells labelled with BODIPY 493/503. Data shows lipid droplet content per cell analysed in 3-5 fields of view ±SD. Scale bar, 25 µm. **e**, HCC1395 and **f**, MDA-MB-231 cells cultured in DMEM or LG DMEM and stained with BODIPY 581/591 C11. Quantification of oxidised (green) BODIPY probe as a ratio of total probe (green plus red) per cell in 4-5 fields of view per sample ±SD. Representative images; scale bar, 50 µm. ns, not significant; *, *P*<0.05; ***, *P*<0.001, unpaired *t*-test (**a-d**). ns, not significant; ***, *P*<0.001, two-way ANOVA with Bonferroni post-testing (**e-f**).

Fig. 6 | Etomoxir treatment blocks AKR1B10-mediated metastasis. **a**, 5x10³ cells seeded into ultra-low adherence U-bottomed plates. 24 h post seeding 200 µM etomoxir or vehicle was added and tumour spheroid viability assessed day 6. *n*=8 ±SD. Equivalent results were obtained in two independent experiments. **b**, BALB/c Nude mice injected intravenously with 1x10⁶ cells and treated with vehicle or etomoxir (*n*=5-7 per group). Lung tumour burden was assessed at the end of the experiment (day 55) by *ex vivo* IVIS imaging (dashed line indicates average radiance of aged-matched non-tumour bearing mice), lung weight and the mean % tumour area from 3 sections cut through the lungs 150 µm apart ±SEM. Representative *ex vivo* IVIS images and lung sections are shown. Scale bar, 1 mm. ns, not significant; *, *P*<0.05; **, *P*<0.01; ***, *P*<0.001; two-way ANOVA with Bonferroni post-testing (**a-b**).